MarsBars/E+ via Getty Images
- Novavax (NASDAQ:NVAX) has submitted an application to the European Medicines Agency seeking authorization of its JN.1 COVID-19 vaccine to be administered starting in the fall.
- The shot is also effective against the KP.2 and KP.3 variants, which alone account for nearly 54% of the cases currently in the U.S., according to CDC data.
- A similar application was submitted to the U.S. FDA earlier in June.